$IBIO We have 3 oncology PR coming, at minimum. IBIO recently announced they were adding 3 oncology products to their pipeline, all 3 with "undisclosed targets" (as show in the attached image). What do you think the next PR will be? Addressing the actual target of these drugs. Not to mentioned the 402 characterization, IBIO 101 updates, updates in respect to 400 and pushing towards FDA approval, and news on the relationship with Safi. As an aside, let's look at Tom's history as it might give us a prediction of the future here. Tom led a turnaround of the Core Microbiology diagnostic business at BD, and then went on to become the founding Vice President of Becton Dickinson’s BD Advanced Bioprocessing business. He took this from $0 revenue, to $60MM in revenue within 3 years...and it was then purchased for $477MM. That is a new division. No platform like IBIO, and without the existing talent. Just imagine what Tom will accomplish in the next year, let alone 3 or 5.